We are fully committed to publishing details about our various forms of collaborations with healthcare professionals (HCPs), healthcare organisations (HCOs) and patient organisations (POs) to demonstrate that we interact with these stakeholders ethically and transparently. These disclosures are aligned with either the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure (Transparency) Code of Conduct, local pharmaceutical codes or national legislation implemented by organisations such as healthcare authorities. The underlying rationale and methodology follow a coherent concept.
Disclosure of Transfers of Value to Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs)
Grünenthal interacts with healthcare professionals on various subjects. This includes seeking advice and/or services from healthcare professionals (e.g. market research about our products, in the course of clinical trials, observations etc.) and informing healthcare professionals about the advantages and medical implications of our products. Interactions with healthcare organisations include sponsorships of medical association meetings, stands at medical association meetings and congresses, as well as donations and grants to hospitals for research and education.
All interactions and transfers of value are disclosed in line with local regulations. These disclosures are aligned with either the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure (Transparency) Code of Conduct, local pharmaceutical codes or national legislation carried out by parties such as healthcare authorities. The underlying rationale and methodology follow a coherent concept.
Disclosure of Transfers of Value to Patient Organisations
Patient organisations provide a powerful voice for patients. They are involved in disease education and provide help lines, emotional support, and access to treatment. On top of this, they are key participants in crucial discussions about the healthcare system and collaborate with a number of stakeholders, including pharmaceutical companies. Relationships with patient organisations are well regulated by the EFPIA Code of Practice on Relationships between the Pharmaceutical Industry and Patient Organisations, as well as by national industry codes of practice. You can find a complete list of all of Grünenthal's transfers of value to patient organisations below.
Disclosure of Transfers of Value to Patient Organisations 2024 (PDF)
Disclosure of Transfers of Value to Patient Organisations 2023 (PDF)
Disclosure of Transfers of Value to Patient Organisations 2022 (PDF)
Disclosure of Transfers of Value related to Research and Development activities
Grünenthal is committed to developing effective and innovative medicines that deliver true benefits for patients and healthcare systems. As part of this commitment, we have an ethical responsibility to ensure the quality and integrity of all research and development activities. The need to support independent ethical clinical research conducted by qualified third-party investigators is key where research and development is concerned. The purpose of such projects is to help to explore new opportunities to address unmet medical needs. Grünenthal supports the funding of research and development projects of this kind.
In the past three years, the total transfers of value to healthcare professionals and healthcare organisations related to research and development activities were as follows (excluding tax):
2023: approximately 21 million euros;
2022: approximately 2.3 million euros;
2021: approximately 1.7 million euros.
Transfers of Value Research & Development 2023 ROW Countries (PDF)
Transfers of Value Research & Development 2022 ROW Countries (PDF)
Transfers of Value Research & Development 2021 ROW Countries (PDF)
Some background on the EFPIA Disclosure
Grünenthal is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and supports the EFPIA Disclosure (Transparency) Code of Conduct. Since 2015, the disclosure process driven by the European Federation of Pharmaceutical Industries and Associations (EFPIA) has been in place. As a result, all transfers of value to healthcare professionals (HCPs) and healthcare organisations (HCOs) have been collected since 2015 and are reported ("disclosed") the year after. This includes:
- Grants and donations to healthcare organisations
- Speaker and consultancy fees for healthcare professionals
- Sponsoring of events organised by, or on behalf of, healthcare organisations
- Invitations of healthcare professionals to congresses and educational or scientific meetings
- Research and development-related transfers of value (only as an aggregated report)
For more information about the EFPIA Transparency Code, please visit the EFPIA website: https://efpia.eu/relationships-code/healthcare-professionals-hcps/
The proposed EFPIA format for the disclosure report is used by the local pharmaceutical associations in Europe, which are direct members of EFPIA. The report defines the different categories and how to disclose transfers of value to healthcare professionals and healthcare organisations on an annual basis.